Scienture Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its liquid formulation of losartan, branded as ArbliTM (losartan potassium) Oral Suspension, at a ...
COMMACK, NY, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced ...
“These milestones significantly expand the commercial opportunity for ARBLI™ and represent an important inflection point in its launch trajectory,” commented Narasimhan Mani, President and co-CEO of ...
Angiotensin Receptor Blockade and the LIFE, VALUE and CHARM Trials The LIFE (Losartan Intervention For Endpoint) reduction of hypertension study was a double-blind, randomised, parallel-group trial ...
The angiotensin receptor blocker (ARB) losartan led to hypotension and failed to improve mortality in patients hospitalized for acute COVID-19, according to the randomized, prospective -- and ...
SARS2-CoV-2 virus utilizes ACE2 to invade host cells; down-regulation of ACE2 can potentially increase Angiotensin II, promote vasoconstriction and inflammation, and promote organ damage in patients ...
Reducing proteinuria with an ARBTelmisartan (Micardis), a novel angiotensin receptor blocker (ARB), and the older ARB losartan (Cozaar) are both effective in hypertensive patients with diabetic ...
Losartan may help stop the epileptic process in certain patients with hypertension. An observational study that analyzed medical records of 2.26 million patients with hypertension found a roughly 30% ...
The observational study reported by Yoshihara et al. [1] on second-generation angiotensin receptor blockers (ARBs) and their association with increased risk of hypotension in hospitalized COVID-19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results